Fewer than one in 10 people that would benefit from weight-loss injections such as Wegovy are able to get them, caution the global health agency as it releases its initial recommendations on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just availability to this class of drugs.
Based on estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our new guidelines acknowledges that obesity is a chronic disease that can be addressed with comprehensive and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant obstacles to universal access to the jabs that can assist patients in reducing considerable body mass, says the body.
GLP-1 Therapy Supply Crisis
Despite the present most optimistic scenario, the supply of GLP-1 therapies might only reach approximately 100 million people – under 10% of those who need them, according to the WHO.
The recommendation encourages governments and firms to expand access, through strategies including licensing agreements.
Exclusive production rights on semaglutide – the core component of the drug Wegovy – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Injections Function
These medications imitate a body's own hormone to slow digestion, reduce hunger and increase the sense of being full so people eat less.
Individuals commonly begin shedding pounds after several weeks of starting on the regular doses.
Research indicates users may put most of the weight back on within a year of stopping the treatment, because their typical appetite come back.
To be carrying excess weight raises your chance for experiencing diseases, including diabetes, heart disease, stroke, and certain malignancies.
Obesity impacts people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.
